We're racing to define aging mechanisms—senescent cell clearance, epigenetic drift, autophagy hierarchies—but we've sidestepped a basic truth: our models don't represent human diversity. Most longevity studies use homogenous cohorts or inbred mice, treating biological variability as background noise. Yet aging trajectories diverge wildly across genetic, environmental, and socioeconomic lines. If a targeted senolytic or reprogramming protocol shows efficacy in one population, will it work in another? We don't know, because we haven't built the tools to ask.

This isn't an ethical footnote; it's a core scientific gap. Without understanding how interventions interact with diverse genetic backgrounds, we're not extending human life—we're engineering a biological aristocracy. Access will follow wealth, geography, and privilege, just like every other medical advancement. But unlike antibiotics or statins, radical life extension could reshape societal structures fundamentally.

The recent focus on niche-specific pathways—like EC-cell serotonin dynamics or gut-brain axis signaling—underscores how context-dependent these mechanisms are. Yet we're still funding reductionist studies that ignore real-world complexity. We need inclusive research frameworks: diverse human cohorts, cross-ancestry GWAS, and collaborations with social scientists to model equity impacts.

Who deserves more life? The field hasn't dared to answer, because we haven't done the work to ensure our science benefits more than a privileged few. Let's fund the diversity gap before we cement a two-tiered species.